323 related articles for article (PubMed ID: 34165771)
1. Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.
Sonousi A; Mahran HA; Ibrahim IM; Ibrahim MN; Elfiky AA; Elshemey WM
Pharmacol Rep; 2021 Dec; 73(6):1754-1764. PubMed ID: 34165771
[TBL] [Abstract][Full Text] [Related]
2. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
3. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
Banerjee A; Kanwar M; Maiti S
Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
[TBL] [Abstract][Full Text] [Related]
4. Binding properties of selective inhibitors of P323L mutated RdRp of SARS-CoV-2: a combined molecular screening, docking and dynamics simulation study.
Chinnamadhu A; Ramakrishnan J; Suresh S; Poomani K
J Biomol Struct Dyn; 2024 May; 42(8):4283-4296. PubMed ID: 37301607
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
6. Computational hunting of natural active compounds as an alternative for Remdesivir to target RNA-dependent polymerase.
Saeed M; Saeed A; Alam MJ; Alreshidi M
Cell Mol Biol (Noisy-le-grand); 2021 Jan; 67(1):45-49. PubMed ID: 34817369
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
[TBL] [Abstract][Full Text] [Related]
8. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.
Olotu FA; Omolabi KF; Soliman MES
Cell Biochem Biophys; 2021 Jun; 79(2):175-187. PubMed ID: 33792836
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Nucleoside-like Molecules from a Pyrolysis Product of Cellulose and Their Computational Prediction as Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors.
Defant A; Dosi F; Innocenti N; Mancini I
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008944
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
11. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.
Tiwari V
Int J Biol Macromol; 2021 Feb; 171():358-365. PubMed ID: 33421473
[TBL] [Abstract][Full Text] [Related]
12. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ
Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855
[TBL] [Abstract][Full Text] [Related]
13. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
14. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
16. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
[TBL] [Abstract][Full Text] [Related]
18. Novel sofosbuvir derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.
Alrehaily A; Elfiky AA; Ibrahim IM; Ibrahim MN; Sonousi A
Sci Rep; 2023 Dec; 13(1):23080. PubMed ID: 38155165
[TBL] [Abstract][Full Text] [Related]
19. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
Jiang Y; Yin W; Xu HE
Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
[TBL] [Abstract][Full Text] [Related]
20. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.
Tchesnokov EP; Gordon CJ; Woolner E; Kocinkova D; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Nov; 295(47):16156-16165. PubMed ID: 32967965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
